Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Fruquintinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms FALUCA
- Sponsors Chi-Med; Hutchison MediPharma; HUTCHMED
- 10 Sep 2019 Results assessing the overall survival and post-hoc sensitivity analysis, presented at the 20th World Conference on Lung Cancer.
- 11 Feb 2019 Status changed from active, no longer recruiting to completed.
- 16 Dec 2018 According to a Chi-Med media release, full detailed results are expected to be disclosed at an upcoming scientific meeting.